Healthcare Industry News: Bellicum Pharmaceuticals
News Release - December 5, 2014
Bellicum Announces New Director, Executive Management Appointments
HOUSTON--(Healthcare Sales & Marketing Network)--Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of a new Director and two senior executives to its management team.- Jon P. Stonehouse has been elected to Bellicum’s Board of Directors. Jon currently serves as President and Chief Executive Officer of BioCryst Pharmaceuticals, Inc.
- Alan Musso has been appointed as Chief Financial Officer and Treasurer. He was most recently Senior Vice President, Finance and Administration, CFO and Treasurer, at Targacept, Inc.
- Peter Hoang has joined as Senior Vice President, Business Development and Strategy. Peter formerly headed the new venture formation and development effort for The University of Texas MD Anderson Cancer Center.
Alan Musso, appointed as Bellicum’s CFO and Treasurer, has over 25 years of biotechnology and pharmaceutical industry experience in both large and emerging growth companies, including capital raising, corporate partnering, finance, strategy and the financial stewardship of publicly-traded companies. Prior to being CFO at Targacept, Inc., he began his career working in the public accounting field at KPMG and later held positions of increasing responsibility with Pfizer. Mr. Musso received a B.S. in Accounting from Saint Mary's College of California, and a master's degree from the American Graduate School of International Management in Glendale, Arizona.
Peter Hoang, appointed as Bellicum’s Senior Vice President, Business Development and Strategy, has over 18 years of finance and deal making experience in investment banking and venture capital. Prior to heading new venture formation and development at MD Anderson, he was a senior investment banker, most recently leading healthcare mergers & acquisitions advisory for CIT Group. He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank. He earned high honors distinction with an M.B.A. from the Anderson School of Management at UCLA and a B.A. from Yale University.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines. For more information, please visit www.bellicum.com
Source: Bellicum Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
